Peptide Decoding
New?New to peptides?Start here →
Decoding

ARA-290 (Cibinetide)_Dosage, benefits & legal status

Also known as cibinetide, ARA290

Published July 22, 2026 · Updated October 5, 2026

A peptide studied for calming nerve pain and inflammation.

Nerve pain & healingEPO-derived peptideInvestigational
Common vial size10 mg
Dose1 up to 4 mg per day (start low, increase slowly)
FrequencyDaily
RouteUnder the skin (subcutaneous)
StatusInvestigational
CycledA 28-day daily course is what has been studied

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

01

What is ARA-290 (Cibinetide)?

Plain language first. The technical label stays, but it never stands alone.

Overview

It keeps only EPO's healing, anti-inflammatory side, switching on a 'repair receptor' in injured nerves and tissue without thickening the blood. It reached real human trials for nerve pain.

The technical version

ARA-290 (cibinetide) is an 11-amino-acid peptide carved from the tissue-protective part of erythropoietin (EPO), the hormone that makes red blood cells.

What it's used for

A peptide studied for calming nerve pain and inflammation, especially in diabetic nerve damage, without affecting red blood cells.

02

How does ARA-290 (Cibinetide) work?

What it does in the body, and where.

ARA-290 is a fragment of erythropoietin with the blood-cell-making part removed, keeping only the tissue-protective side.

  1. 01
    It activates the innate repair receptor
    A different receptor from the one EPO uses to make red blood cells, which is why this fragment can be separated out.
  2. 02
    Inflammation calms and nerve tissue repairs
    The effect studied in small-fibre neuropathy and sarcoidosis.
  3. 03
    It does not raise red blood cells
    Which is the whole design goal. EPO's clotting risk comes from that effect, and removing it removes the risk.
  4. 04
    Human trials are small but real
    Unlike most of this category, it has completed placebo-controlled trials in people, with modest results.
Anatomical illustration highlighting brain
WHERE THIS COMPOUND IS THOUGHT TO ACT:
Nerve

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Nerve pain in sarcoidosis, which reached Phase 2 trialsInvestigational
  • Nerve damage from diabetesInvestigational
  • Inflammation and tissue repair generallyEarly research

The published record

Research index

82

Papers and trials about ARA-290 (Cibinetide)

Searched: ARA-290, cibinetide, ARA290.

38 papers tagged human · 18 not reviews or lab · 5 clinical trial publications

4 registered trials · 1 with posted results

Furthest stage reached: Phase 2, results posted

Compare this against the whole library →

Category 3Regulators
In animals46
In the lab13
Reviews10
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.

ARA-290 (Cibinetide) vial rendering
Compound field notes

At a glance

Four things to know about ARA-290 (Cibinetide)

01

Evidence

Investigational

02

Category

Healing and recovery

03

Common vial

10 mg

04

Half-life

About 20 minutes injected, about 2 minutes into a vein

04

How much, and do you cycle it?

The range, and whether you take breaks.

1 up to 4 mg per day (start low, increase slowly), daily. A 28-day daily course is what has been studied Trial dose

The phase 2 trials in small-fibre neuropathy and type 2 diabetes ran daily injections for 28 days and stopped. That is the only duration with human data behind it. Nothing has been published on repeating the course or on how long to wait before doing so.

Source: ARA-290 in sarcoidosis small-fibre neuropathy, 28-day daily course (NCT02039687)

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

About 20 minutes injected, about 2 minutes into a veinTrial protocol

The biological effect lasts 24 to 72 hours, far longer than the peptide itself. The 4 to 8 hours quoted on vendor sites is wrong.

Source: Expert Opin Orphan Drugs 2013;1(1):77-87, DOI 10.1517/21678707.2013.719289

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Printed on the vial.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: 1 up to 4 mgHuman study

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW20 / 100 units
What it costs

ARA-290 (Cibinetide) starts at $23.62 across 92 vendors, typically $3.44 – $6.50 per mg.

111 listings, last read Oct 24, 2026. Shipping and card fees are not included.

See all 111 listings →
07

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized ARA-290 (Cibinetide) keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 45% charged residues, 27% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • No formal contraindications established in trials

Stop and get help

These are emergencies. Seek care.
  • Signs of an allergic reaction

Common effects

Expected, and usually mild.
  • Well tolerated across Phase 2 trials with no safety concerns identified
  • Unlike the hormone it is derived from, it does not thicken the blood

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is ARA-290 (Cibinetide) approved?

And where the numbers on this page come from.

No. ARA-290 (Cibinetide) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

  • Approval status
    Investigational
  • Route
    Under the skin (subcutaneous)
  • Checked
    22 July 2026
  • Dose
    From published human studies. Not approved by a regulator for this dose.
  • Vial size
    From what vendors typically list; not a recommendation.
  • Sources
    None traced yet.

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

What regulators say

From official documents

Guides for this compound

Sources

No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence

Beyond these, 82 records are indexed. Browse the records